<DOC>
	<DOCNO>NCT00752037</DOCNO>
	<brief_summary>A single center , open label , 48-week study lopinavir/ritonavir combination raltegravir . 30 patient , naïve experience , enrol . 15 treatment naïve patient 15 treatment experience patient enrol</brief_summary>
	<brief_title>Safety Study Lopinavir/Ritonavir With Raltegravir HIV-infected Patients</brief_title>
	<detailed_description>This open-labeled , non-randomized exploratory trial select volunteer meet stated enrollment criterion . This study assess impact lopinavir/ritonavir combination raltegravir HIV-1 Patients evaluate frequently 52 week protocol . Patients see screen , baseline , week 4 , 12 , 24 , 36 , 48 , 52 , include physical examination , assessment development AIDS-defining condition , hematology , chemistry , lipid profile , CD4 , CD8 cell count , plasma HIV-1 RNA ultrasensitive , assessment adverse event . If HIV-1 RNA become detectable , repeat confirmation 2 week . HIV genotyping phenotyping performed patient demonstrate repetitive plasma viral load level &gt; 1,000 copies/mL . An interim analysis perform patient reach week 24 visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . HIV1 infection , document licensed ELISA test kit , confirm Western blot , positive HIV1 blood culture , positive HIV serum antigen , plasma viremia time prior study entry . If record exist , test must occur screen . 2 . Males nonpregnant female &gt; 18 year age . ( Children exclude immunologically different adult ) 3 . HIV1 RNA &gt; 1000 copies/ml patient naive experienced antiretroviral therapy order phenotypic susceptibility perform . There inclusion criterion CD4 count . 4 . Treatment experience patient , define take medication two follow three class antiretrovirals : NRTI , NNRTI , PI must phenotypic susceptability lopinavir/ritonavir result Phenosense GT 5 . Laboratory test ( Cbc w/diff , comprehensive metabolic panel ) within prespecified limit 6 . Able sign inform consent , willing comply requirement clinical trial . 7 . Available least 52 week follow 8 . If female child bear potential must consent remain abstinent throughout study period 30 day last dose study medication . ( standard language ) 1 . Pregnant breastfeed woman ( pregnant woman exclude drug kinetics different pregnancy dynamic immune reconstitution unknown group ) 2 . Current treatment malignancy basal squamous cell carcinoma skin carcinoma situ cervix isolate cutaneous Kaposi 's Sarcoma treat ; prior cancer diagnosis , lymphoma must diseasefree least 5 year 3 . Absolute neutrophil count &lt; 500 , platelet count &lt; 50,000 , hemoglobin &lt; 8 gm/dL 4 . Evidence endorgan disease , define follow : renal ( calculated creatinine clearance le 50 mL/min ) ; liver ( liverassociated enzymes &gt; 3 time upper limit normal ) 5 . Grade 3 ( ACTG Grading Scale ) high cholesterol triglyceride elevation 6 . Acute , serious infection require prescription drug therapy within 30 day prior study entry 7 . In opinion investigator , evidence active ongoing opportunistic infection 8 . Must currently undergo treatment opportunistic infection . 9 . Use immune stimulation agent know impact CD4 cell count peripheral circulation , include IL2 , interferon , GCSF , GMCSF , etc . 10 . Use immune suppressant drug , exception &lt; 10 mg/day prednisone . 11 . Unwillingness remain abstinent duration study 12 . Experimental vaccine , include HIV vaccine . 13 . Patient currently enrol experimental protocol , receive experimental medication . 14 . Patients 2 NRTIs NNRTI PI combination allow study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>HIV</keyword>
	<keyword>Protease Inhibitor</keyword>
	<keyword>Integrase Inhibitor</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>Naive</keyword>
</DOC>